Education

A, 1991, Biochemical Sciences, Harvard College, Cambridge, MA
MD, 1995, Medicine, Johns Hopkins School of Medicine, Baltimore, MD
General surgery & urology, UCSF, 1995-2001
Laparoscopic fellowship, UCSF, 2001-2002
Oncology fellowship, UCSF, 2002-2003

Honors & Awards

  • 1987
    Westinghouse Science Talent Search, 7th Place
  • 1991
    Magna cum laude, Harvard College
  • 1995
    Alpha Omega Alpha, Johns Hopkins
  • 1999
    Third Prize, Northern California Urology Residents Seminar
  • 1999
    Pfizer Scholar in Urology
  • 2001
    Joseph F. McCarthy Essay Contest, 3rd Place, Western Section AUA
  • 2002
    Prostate Cancer Research Fellow
  • 2004
    William R. Smart Distinguished Teaching Award (selected by residents)
  • 2005
    Excellence in Direct Teaching, Academy of Medical Educators, UCSF
  • 2006
    Ambrose/Reed Socioeconomic Prize Essay (AUA)
  • 2006
    AUA leadership Program (1 of 16 selected nationally biennially)
  • 2006
    Miley B. Wesson Essay Contest, 2nd Place, AUA

Selected Publications

  1. Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP. Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. Urol Oncol. 2021 Jul 08.  View on PubMed
  2. Meng M, Wang XS, Li KY, Deng ZX, Zhang ZZ, Sun YL, Zhang SF, He L, Guo JW. Effects of surface roughness on the time-dependent wear performance of lithium disilicate glass ceramic for dental applications. J Mech Behav Biomed Mater. 2021 09; 121:104638.  View on PubMed
  3. Chappidi MR, Welty C, Choi W, Meng MV, Porten SP. Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology. 2021 Jun 10.  View on PubMed
  4. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 Sep 15; 27(18):5123-5130.  View on PubMed
  5. Chan VW, Tan WS, Leow JJ, Tan WP, Ong WLK, Chiu PK, Gurung P, Pirola GM, Orecchia L, Liew MPC, Lee HY, Wang Y, Chen IA, Castellani D, Wroclawski ML, Mayor N, Sathianathen NJ, Braga I, Liu Z, Moon D, Tikkinen K, Kamat A, Meng M, Ficarra V, Giannarini G, Teoh JY. Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World J Urol. 2021 May 24.  View on PubMed
  6. Tang S, Meng MV, Slater JB, Gordon JW, Vigneron DB, Stohr BA, Larson PEZ, Wang ZJ. Metabolic imaging with hyperpolarized 13 C pyruvate magnetic resonance imaging in patients with renal tumors-Initial experience. Cancer. 2021 Aug 01; 127(15):2693-2704.  View on PubMed
  7. Balakrishnan AS, Hampson LA, Bell AM, Baghdanian AH, Baghdanian AA, Meng MV, Odisho AY. Evaluating the impact of surgical supply cost variation during partial nephrectomy on patient outcomes. Transl Androl Urol. 2021 Feb; 10(2):765-774.  View on PubMed
  8. Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP. Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology. 2021 Mar; 149:168-173.  View on PubMed
  9. Washington SL, Gregorich SE, Meng MV, Suskind AM, Porten SP. Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. Cancer Med. 2020 11; 9(22):8310-8317.  View on PubMed
  10. de la Calle CM, Washington SL, Lonergan PE, Meng MV, Porten SP. Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. World J Urol. 2021 Jun; 39(6):1911-1916.  View on PubMed
  11. Zuniga KB, Washington SL, Porten SP, Meng MV. Correction to: A comparison of stage-specific all-cause mortality between testicular sex cordstromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 07 17; 20(1):103.  View on PubMed
  12. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 06 25; 181(7):1612-1625.e13.  View on PubMed
  13. Zuniga KB, Washington SL, Porten SP, Meng MV. A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 Apr 17; 20(1):40.  View on PubMed
  14. Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA. Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. Bladder Cancer. 2020; 6(1):9-23.  View on PubMed
  15. Chu CE, Porten SP, Grossfeld GD, Meng MV. Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Urol Clin North Am. 2020 Feb; 47(1):111-118.  View on PubMed
  16. Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer. 2019 Aug 07; 3(2):111-118.  View on PubMed
  17. Washington SL, Neuhaus J, Meng MV, Porten SP. Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2019 08; 28(8):1339-1344.  View on PubMed
  18. Herlemann A, Meng MV. Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019? BJU Int. 2019 05; 123(5):744-746.  View on PubMed
  19. Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer. J Urol. 2019 12; 202(6):1111-1119.  View on PubMed
  20. Balakrishnan AS, Washington SL, Meng MV, Porten SP. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e461-e471.  View on PubMed

Go to UCSF Profiles, powered by CTSI